Evidence map›Paper›PMID 26519463›Full record

ArticleJournal of Crohn's & colitis2016

Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease.

Severine Vermeire, Marie Joossens, Kristin Verbeke, Jun Wang, Kathleen Machiels, João Sabino, Marc Ferrante, Gert Van Assche, Paul Rutgeerts, Jeroen Raes

3 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Crohn's & colitis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 170 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03483246 phase3active not recruitingnot on this mapstarted 2018, after this paper: background citation

Impact of Fecal Microbiota Transplantation in Ulcerative Colitis: a Randomized, Sham Controlled Trial

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2018 to 2027Enrolled150ConditionsUlcerative ColitisArmsFecal Microbiota Transplantation (FMT), Sham-transplantation Placebo
NCT03817125 phase1completednot on this mapstarted 2019, after this paper: background citation

A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic Melanoma

TypeinterventionalSponsorParker Institute for Cancer ImmunotherapyRan2019 to 2022Enrolled14ConditionsMetastatic MelanomaArmsPlacebo for antibiotic, Vancomycin pretreatment, Nivolumab, Matching Placebo for SER-401, SER-401
NCT04997733 phase3recruitingnot on this mapstarted 2021, after this paper: background citation

Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2021 to 2029Enrolled150ConditionsCrohn DiseaseArmsFecal Microbiota Transplantation (FMT), Sham-transplantation (placebo)
3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Review

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Severine VermeireKU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), University Hospitals Leuven, Leuven, Belgium Severine.Vermeire@uzleuven.be.
Marie Joossens
Kristin VerbekeKU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), University Hospitals Leuven, Leuven, Belgium.
Jun WangKU Leuven, Department of Microbiology and Immunology, Rega Institute, Leuven, Belgium VIB, Center for the Biology of Disease, Leuven, Belgium.
Kathleen MachielsKU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), University Hospitals Leuven, Leuven, Belgium.
João SabinoKU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), University Hospitals Leuven, Leuven, Belgium.
Marc FerranteKU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), University Hospitals Leuven, Leuven, Belgium.
Gert Van AsscheKU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), University Hospitals Leuven, Leuven, Belgium.
Paul RutgeertsKU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), University Hospitals Leuven, Leuven, Belgium.
Jeroen RaesKU Leuven, Department of Microbiology and Immunology, Rega Institute, Leuven, Belgium VIB, Center for the Biology of Disease, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsFaecal microbiota transplantation is a successful therapy for patients with refractory Clostridium difficile infections. It has also been suggested as a treatment option for inflammatory bowel disease, given the role of the intestinal microbiota in this disease. We assessed the impact of faecal microbiota transplantation in patients with inflammatory bowel disease and studied predictors of clinical (non-)response in microbial profiles of donors and patients.

methodsFourteen refractory patients (8 with ulcerative colitis and 6 with Crohn's disease) underwent ileocolonoscopy with faecal microbiota transplantation through a nasojejunal (n = 9) or rectal (n = 5) tube. Efficacy was assessed by endoscopic healing at week 8, clinical activity scores and C-reactive protein measurement. Faecal microbiota was analysed by 16S rDNA pyrosequencing.

resultsThere was no significant improvement among the 6 patients with Crohn's disease at week 8 following faecal microbiota transplantation. One patient experienced temporary clinical remission for 6 weeks. In contrast, 2/8 patients with ulcerative colitis had endoscopic remission at week 8, and of the 6 remaining patients with ulcerative colitis, 1 reported temporary remission for 6 weeks. The donor microbiota richness and the number of transferred phylotypes were associated with treatment success. Persistent increased C-reactive protein 2 weeks after transplantation was predictive of failure of response.

conclusionFaecal microbiota transplantation led to endoscopic and long-term (>2 years) remission in 2 out of 8 ulcerative colitis patients. Higher donor richness was associated with successful transplant. Therefore, faecal microbiota transplantation with donor prescreening could be a treatment option for selected refractory ulcerative colitis patients.

Indexed as

Fecal Microbiota TransplantationGastrointestinal MicrobiomeAdultColitis, UlcerativeColonoscopyC-Reactive ProteinCrohn DiseaseFemaleHumansInflammatory Bowel DiseasesMaleMiddle AgedTreatment FailureTreatment OutcomeC-Reactive ProteinFaecal microbiota transplantation (FMT)OscillibacterRoseburia

Identifiers

PMID26519463
PMCPMC4946755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.